oric-944

oric-944: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.

Development Pipeline (1)

Clinical Trials (1)

An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer

NCT05413421·Phase 1·ORIC
Recruiting

Frequently asked questions

Who is developing oric-944?

oric-944 is being developed by Oric Pharmaceuticals, Inc..

How many clinical trials involve oric-944?

BioSniper tracks 1 clinical trial involving oric-944.

Get deeper analysis on oric-944

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis